| Literature DB >> 28784865 |
Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W Behrman, Al B Benson, Ellen Binder, Dana B Cardin, Charles Cha, E Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R Ferrone, Jeffrey Hardacre, William G Hawkins, Joseph Herman, Andrew H Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M Lowy, Cassadie Moravek, Eric K Nakakura, Eileen M O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D Weekes, Robert A Wolff, Brian M Wolpin, Jennifer Burns, Susan Darlow.
Abstract
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.Entities:
Mesh：
Year: 2017 PMID： 28784865 DOI： 10.6004/jnccn.2017.0131
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908